Recordati Rare Diseases Announce Publication of Long-term Outcomes From the Extension to the Phase III LINC 3 Study of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease in the European Journal of Endocrinology

Long-term findings from the multicentre, international LINC 3 study demonstrated that treatment with Isturisa® (osilodrostat) maintains cortisol normalisation and is well tolerated in most patients with Cushing’s disease. PUTEAUX, France–(BUSINESS WIRE)–Recordati Rare Diseases announce today publication of the long-term outcomes from the open-label extension period of the Phase III LINC 3 study of Isturisa® in … [Read more…]

LEO Pharma Appoints Paul Navarre New Member of Its Board of Directors

BALLERUP, Denmark–(BUSINESS WIRE)–LEO Pharma today announced the appointment of Paul Navarre as new member of its Board of Directors. Paul Navarre currently serves as chairman of the Board of Directors at HTL (dermatology) and Arkopharma (Dietary Supplements), as Vice Chairman of Hallura (dermatology) and as Strategic Advisor to other companies. From 2017-2020 he held the … [Read more…]

Bill to Convert Buildings into Affordable Housing Clears CA Assembly Unanimously

California Assembly Bill 1695 (Miguel Santiago, D-53rd District) makes adaptive reuse of existing buildings permanently eligible for the state’s affordable multifamily housing loan programs The bill, which defines ‘adaptive reuse’ to mean the retrofitting and repurposing of an existing building to create new residential units, cleared the Assembly unanimously earlier today and now heads to … [Read more…]

InnoCare Announces the Acceptance of the Biologics License Application for Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969) announced today the acceptance of the biologics license application (BLA) for tafasitamab in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT) by the Department of Health, the Hong Kong Special Administrative Region, China. … [Read more…]

Parsemus Foundation: Common and Affordable Drug Can Drastically Reduce COVID Complications, Study Shows

Metformin reduced emergency room visits, hospitalization, and death from COVID-19 by more than half if started within 4 days of symptoms SAN FRANCISCO–(BUSINESS WIRE)–The widely available diabetes drug metformin reduced serious COVID outcomes by more than half if started within 4 days of symptoms, in a large, double-blind, randomized, controlled trial conducted by the University … [Read more…]

Vista Living Expands Assisted Living and Memory Care Service to Paradise Valley, Arizona

PARADISE VALLEY, Ariz.–(BUSINESS WIRE)–Vista Living Senior Care, Inc. is proud to announce the opening its fourth assisted living home in the Phoenix area and the first in Paradise Valley. The other three homes are in the Arcadia neighborhood on the other side of Camelback Mountain. The new home offers a similarly welcoming and intimate experience … [Read more…]

MultiPlan Corporation Announces Participation at Upcoming Conferences

NEW YORK–(BUSINESS WIRE)–MultiPlan Corporation (NYSE:MPLN) (“MultiPlan” or the “Company”), a leading value-added provider of data analytics and technology-enabled end-to-end cost management, payment and revenue integrity solutions to the U.S. healthcare industry, today announced that members of its management team will participate in person at the following conferences in September 2022: Morgan Stanley 20th Annual Global … [Read more…]

Baxter to Present at the 2022 Wells Fargo Healthcare Conference

DEERFIELD, Ill.–(BUSINESS WIRE)–Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 10:25 a.m. Eastern Time. The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for … [Read more…]

Alpine Immune Sciences Announces R&D Day to Provide Clinical Updates on Wholly-Owned Programs ALPN-303 and Davoceticept

– Clinical data update from a first-in-human phase 1 study of ALPN-303 in healthy adults and plans for multiple patient-based studies beginning in 2023 – – First look at data from NEON-2 study of davoceticept in combination with pembrolizumab in advanced malignancies – – Disease experts to discuss the current treatment landscape and unmet medical … [Read more…]

Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

SAN FRANCISCO–(BUSINESS WIRE)–$SPRB #Tildacerfont—Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Samir Gharib, President and Chief Financial Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022 at 5:00 … [Read more…]